Mesenchymal stem cell therapy in horses: useful beyond orthopedic injuries?

Schauwer, Catharina De; Walle, Gerlinde R. Van de; Soom, Ann Van; Meyer, Evelyne

doi:10.1080/01652176.2013.800250

Cited by 51 publications

(37 citation statements)

References 77 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, cellular therapies including application of stem progenitor cells hold great promise in the treatment of diabetes type 2 in humans . In turn, in equine veterinary medicine practice, stem progenitor cells are widely used, and these type of therapies are well accepted in veterinary society . However, the cytophysiological conditions of progenitor cells, used for engraftment seems to be fundamental factor, that might determine the effectiveness of clinical therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Finally, ASC possess ability to differentiation in vitro into multiple cell lineages including osteocytes, chondrocytes, myocytes and neurons . These features seem to be crucial, from clinical perspective, especially, that in the last decade equine cellular therapies in treatment of various musculoskeletal disorders are widely applied in veterinary clinical practice .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Equine metabolic syndrome impairs adipose stem cells osteogenic differentiation by predominance of autophagy over selective mitophagy

Marycz

Kornicka

Marędziak

et al. 2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

Adipose‐derived mesenchymal stem cells (ASC) hold great promise in the treatment of many disorders including musculoskeletal system, cardiovascular and/or endocrine diseases. However, the cytophysiological condition of cells, used for engraftment seems to be fundamental factor that might determine the effectiveness of clinical therapy. In this study we investigated growth kinetics, senescence, accumulation of oxidative stress factors, mitochondrial biogenesis, autophagy and osteogenic differentiation potential of ASC isolated from horses suffered from equine metabolic syndrome (EMS). We demonstrated that EMS condition impairs multipotency/pluripotency in ASCs causes accumulation of reactive oxygen species and mitochondria deterioration. We found that, cytochrome c is released from mitochondria to the cytoplasm suggesting activation of intrinsic apoptotic pathway in those cells. Moreover, we observed up‐regulation of p21 and decreased ratio of Bcl‐2/BAX. Deteriorations in mitochondria structure caused alternations in osteogenic differentiation of ASCEMS resulting in their decreased proliferation rate and reduced expression of osteogenic markers BMP‐2 and collagen type I. During osteogenic differentiation of ASCEMS, we observed autophagic turnover as probably, an alternative way to generate adenosine triphosphate and amino acids required to increased protein synthesis during differentiation. Downregulation of PGC1α, PARKIN and PDK4 in differentiated ASCEMS confirmed impairments in mitochondrial biogenesis and function. Hence, application of ASCEMS into endocrinological or ortophedical practice requires further investigation and analysis in the context of safeness of their application.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Equine metabolic syndrome impairs adipose stem cells osteogenic differentiation by predominance of autophagy over selective mitophagy

Marycz

Kornicka

Marędziak

et al. 2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…In marked contrast, regenerative MSCs-based therapy for tendon/ligament lesions -either traumatic or degenerative -has not been attempted at all in dogs, while this research field is extensively explored in both humans and horses (Park et al 2010;Alberton et al 2012;De Schauwer et al 2013). However, many of the tendon/ligament injuries, i.e.…”

Section: Therapeutic Applications Of Canine Mesenchymal Stem Cellsmentioning

confidence: 99%

“…Another complication is the fact that this treatment is often combined with diverse biological factors, including BM supernatant, autologous serum, platelet-rich plasma, etc. (Clegg & Pinchbeck 2011;De Schauwer et al 2013). Finally, little information is available regarding short-term and longterm safety of SC therapy in veterinary medicine.…”

Section: Introductionmentioning

confidence: 99%

Canine mesenchymal stem cells: state of the art, perspectives as therapy for dogs and as a model for man

Bakker

Ryssen

Schauwer

et al. 2013

Veterinary Quarterly

Self Cite

View full text Add to dashboard Cite

Interest in mesenchymal stem cells (MSCs) both for regenerative and reparative therapies in dogs is emerging, as the current treatment options for several conditions often do not result either in the desired clinical outcome or in the patients' return to normal function. In addition, canine MSCs have been evaluated in some experimental and preclinical studies on efficacy and safety testing of novel treatments for humans, since the dog is considered to be a superior model for humans than rodents. Although these MSCs can be derived from several sources, clinical use has favoured bone marrow and adipose tissue because of their relative ease of stem cell recovery and the minimal donor-site morbidity. Before any type of stem cell can be applied clinically, its unequivocal characterization by a set of specific functional or phenotypic markers is crucial. However, no uniform characterization criteria are available for canine MSCs so far. Moreover, although multi-lineage potential of canine MSCs has been demonstrated in a limited number of studies, research on the differentiation potential of MSCs towards tenocytes is still lacking in canine medicine. In contrast, this latter subject has been explored already in human as well as in equine medicine, demonstrating the need for a specific 'niche', i.e. factors with a positive influence on the MSC differentiation. Since most of these factors are still unknown regarding canine MSC, critical basic knowledge is urgently required to motivate and correctly translate the potential therapeutic applications of these stem cells in both dog and man.

show abstract

“…MSCs have been studied in a wide variety of animal species, including mice, rats, rabbits, dogs, and horses [Jafarian et al, 2008;De Schauwer et al, 2013]. Similar to humans, the MSCs can be isolated from these animals, making animal models useful for understanding the mechanisms and applicable approaches in the clinical setting.…”

Section: Clinical Application Of Mscs For Bone Healingmentioning

confidence: 99%

Role of Mesenchymal Stem Cells in Bone Regenerative Medicine: What Is the Evidence?

Oryan

Kamali²,

Moshiri³

et al. 2017

Cells Tissues Organs

285

204

View full text Add to dashboard Cite

Healing and regeneration of bone injuries, particularly those that are associated with large bone defects, are a complicated process. There is growing interest in the application of osteoinductive and osteogenic growth factors and mesenchymal stem cells (MSCs) in order to significantly improve bone repair and regeneration. MSCs are multipotent stromal stem cells that can be harvested from many different sources and differentiated into a variety of cell types, such as preosteogenic chondroblasts and osteoblasts. The effectiveness of MSC therapy is dependent on several factors, including the differentiating state of the MSCs at the time of application, the method of their delivery, the concentration of MSCs per injection, the vehicle used, and the nature and extent of injury, for example. Tissue engineering and regenerative medicine, together with genetic engineering and gene therapy, are advanced options that may have the potential to improve the outcome of cell therapy. Although several in vitro and in vivo investigations have suggested the potential roles of MSCs in bone repair and regeneration, the mechanism of MSC therapy in bone repair has not been fully elucidated, the efficacy of MSC therapy has not been strongly proven in clinical trials, and several controversies exist, making it difficult to draw conclusions from the results. In this review, we update the recent advances in the mechanisms of MSC action and the delivery approaches in bone regenerative medicine. We will also review the most recent clinical trials to find out how MSCs may be beneficial for treating bone defects.

show abstract

Mesenchymal stem cell therapy in horses: useful beyond orthopedic injuries?

Cited by 51 publications

References 77 publications

Equine metabolic syndrome impairs adipose stem cells osteogenic differentiation by predominance of autophagy over selective mitophagy

Equine metabolic syndrome impairs adipose stem cells osteogenic differentiation by predominance of autophagy over selective mitophagy

Canine mesenchymal stem cells: state of the art, perspectives as therapy for dogs and as a model for man

Role of Mesenchymal Stem Cells in Bone Regenerative Medicine: What Is the Evidence?

Contact Info

Product

Resources

About